Herbalife Nutrition Ltd vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Herbalife Nutrition Ltd trades at $12.87 (market cap $1.34B), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.74B). The key difference: Nuvation Bio Inc. Class A Common Stock is the larger of the two by market cap, and Herbalife Nutrition Ltd is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| HLF | NUVB | |
|---|---|---|
Market Cap | $1.34B | $1.74B |
Volume | 1,589,457 | 9,289,619 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $9.54 |
52-Week Low | $7.75 | $3.41 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $3.18B | $1.33B |
Signals from Pluang's Aura AI — not financial advice
HLF trades at $12.65, up 0.56% today, with a bullish technical signal from moving averages. The stock shows attractive valuation with a P/E of 8.22 and P/S of 0.26. Recent earnings were mixed, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses. The company announced a $250 million share repurchase program and a CEO transition effective October 31, 2026. Cash flow trends show improvement, with 2026 projected net cash flow turning positive at $50 million.
The outlook is cautiously optimistic, supported by analyst consensus price target of $19.00 implying significant upside. Key opportunities include debt reduction progress and margin expansion plans. Risks include inconsistent earnings performance, high debt levels, and investor scrutiny following the CEO transition. The stock remains a value play if execution improves.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →